Immune mechanisms of toxicity from checkpoint inhibitors
Trends in Cancer · 2023-07 · 9 (7) · 543-553
DOI: 10.1016/j.trecan.2023.04.002 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Trends in Cancer, 2023-07. Verfasst von S Jennifer Wang und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA, USA. Hauptthemen laut MEDLINE: Immune Checkpoint Inhibitors, Immunotherapy, Neoplasms, Inflammation. Die Arbeit wurde bisher 307-mal zitiert (Crossref) und nennt 66 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIAID NIH HHS, NCI NIH HHS, American Cancer Society.
Abstract (Originalsprache)
Immunotherapy has changed the treatment landscape for cancer over the past decade. Inhibitors of the immune checkpoint proteins cytotoxic T lymphocyte antigen (CTLA)-4, programmed death (PD)-1, and PD ligand 1 (PD-L1) can induce durable remissions in a subset of patients with metastatic disease. However, these treatments can be limited by inflammatory toxicities that can affect any organ system in the body and in some cases can be life threatening. Considerable progress has been made in understanding the drivers of these toxicities as well as effective management strategies. Further research into understanding the molecular and cellular mechanisms that drive toxicity will enable better prediction of toxicity and development of optimized therapies for these toxicities that avoid interfering with antitumor immunity. In this review, we discuss our current understanding of the inflammatory toxicities from immune checkpoint inhibitors (ICIs) and propose optimal treatment strategies for these toxicities.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA, USA.
- Department of Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA, USA; Harvard Medical School, Boston, MA, USA.
- Harvard Medical School, Boston, MA, USA; Division of Gastroenterology, Massachusetts General Hospital, Boston, MA, USA. Electronic address: michael_dougan@dfci.harvard.edu.
Förderung
- NIAID NIH HHS
- NCI NIH HHS
- American Cancer Society
- NIAID
- Eli Lilly and Company
- Melanoma Research Alliance
Zitieren
APA
Wang, S. J., Dougan, S. K., & Dougan, M. (2023). Immune mechanisms of toxicity from checkpoint inhibitors. Trends in Cancer, 9(7), 543-553. https://doi.org/10.1016/j.trecan.2023.04.002
Vancouver
Wang SJ, Dougan SK, Dougan M. Immune mechanisms of toxicity from checkpoint inhibitors. Trends in Cancer. 2023;9(7):543-553. doi:10.1016/j.trecan.2023.04.002
BibTeX
@article{Wang2023,
author = {Wang, S Jennifer and Dougan, Stephanie K and Dougan, Michael},
title = {Immune mechanisms of toxicity from checkpoint inhibitors},
journal = {Trends in Cancer},
year = {2023},
volume = {9},
number = {7},
pages = {543--553},
doi = {10.1016/j.trecan.2023.04.002}
}
EUVIMED